NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis $7.19 +0.19 (+2.71%) Closing price 04:00 PM EasternExtended Trading$7.18 -0.01 (-0.14%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Day One Biopharmaceuticals Stock (NASDAQ:DAWN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DAWN alerts:Sign Up Key Stats Today's Range$6.88▼$7.2450-Day Range$6.16▼$7.9352-Week Range$6.08▼$16.76Volume1.61 million shsAverage Volume1.15 million shsMarket Capitalization$728.78 millionP/E RatioN/ADividend YieldN/APrice Target$29.00Consensus RatingBuy Company Overview Day One Biopharmaceuticals (NASDAQ:DAWN) is a clinical-stage biotechnology company dedicated to developing precision therapies for patients with solid tumors. The company’s research focuses on designing small molecules that target key drivers of cancer growth and survival, including hormone receptors and cell cycle regulators. Its lead candidate, camizestrant, is an oral selective estrogen receptor degrader (SERD) currently in late-stage development for the treatment of estrogen receptor-positive, HER2-negative advanced breast cancer. Beyond its lead program, Day One leverages a proprietary discovery platform to advance additional candidates across multiple oncology targets. Early-stage assets include novel molecules aimed at disrupting oncogenic signaling and DNA damage repair pathways. The company’s pipeline strategy emphasizes differentiated mechanisms of action designed to address areas of high unmet medical need and to overcome resistance to existing therapies. Founded in 2018 and headquartered in San Francisco, Day One Biopharmaceuticals completed its initial public offering in mid-2021. The company maintains research operations in San Diego and supports clinical development through collaboration with trial sites across North America and Europe. This geographic footprint enables Day One to enroll a diverse patient population and to expedite regulatory interactions with health authorities in key markets. Day One’s leadership team is led by Chief Executive Officer David Meek, a seasoned biotech executive with more than two decades of experience in oncology drug development and commercialization. The management team also includes veterans from leading pharmaceutical and biotechnology companies, bringing deep expertise in clinical operations, regulatory affairs, and global commercial planning. Under this guidance, Day One is positioned to advance its pipeline toward potential regulatory approval and to deliver new treatment options for cancer patients.AI Generated. May Contain Errors. Read More Day One Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreDAWN MarketRank™: Day One Biopharmaceuticals scored higher than 39% of companies evaluated by MarketBeat, and ranked 719th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDay One Biopharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Day One Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($0.72) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -10.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -10.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Day One Biopharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.89% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 32.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.89% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 32.06%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Day One Biopharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows2 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $167,298.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Stock News HeadlinesDAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More - NasdaqJuly 8 at 12:42 AM | nasdaq.comWhen Will Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Breakeven?July 1, 2025 | finance.yahoo.comThis Cold War “Accident” Could Unleash New $100 Trillion AI BoomObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.July 10 at 2:00 AM | Brownstone Research (Ad)Day One Biopharmaceuticals Inc News (DAWN) - Investing.comJune 24, 2025 | investing.comTimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN)June 23, 2025 | msn.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | finance.yahoo.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | globenewswire.comH.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PTJune 5, 2025 | msn.comSee More Headlines DAWN Stock Analysis - Frequently Asked Questions How have DAWN shares performed this year? Day One Biopharmaceuticals' stock was trading at $12.67 at the beginning of 2025. Since then, DAWN stock has decreased by 43.3% and is now trading at $7.19. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its earnings results on Tuesday, May, 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.11. The business had revenue of $30.76 million for the quarter, compared to analyst estimates of $30.28 million. Day One Biopharmaceuticals had a negative net margin of 42.66% and a negative trailing twelve-month return on equity of 14.98%. Read the conference call transcript. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Day One Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings5/06/2025Today7/10/2025Next Earnings (Estimated)7/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Day One Biopharmaceuticals$29.00 High Price Target$36.00 Low Price Target$25.00 Potential Upside/Downside+303.3%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.50 million Net Margins-42.66% Pretax Margin-38.25% Return on Equity-14.98% Return on Assets-13.04% Debt Debt-to-Equity RatioN/A Current Ratio10.62 Quick Ratio10.55 Sales & Book Value Annual Sales$131.16 million Price / Sales5.56 Cash FlowN/A Price / Cash FlowN/A Book Value$4.99 per share Price / Book1.44Miscellaneous Outstanding Shares101,360,000Free Float95,078,000Market Cap$728.78 million OptionableOptionable Beta-1.27 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:DAWN) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.